Cancer Conversations™ in Melanoma: How New Data Are Changing Current Therapeutic Algorithms

Gain expert insight on managing melanoma from newly diagnosed disease through relapsed disease along with an overview of novel therapies in this interactive webinar discussion.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the event.

Agenda

Welcome and Introduction

Adjuvant and Neoadjuvant Therapy
A discussion of approved adjuvant therapies, deciding between immunotherapy and targeted therapy, and recent evidence on neoadjuvant therapy

Therapy Selection for Metastatic Melanoma
Key factors for selecting therapy in the frontline setting and for progressive disease, the clinical role of triple therapy with checkpoint inhibitors and targeted agents, and selection of therapy for patients with brain metastases

Novel Therapies in Melanoma
The latest evidence on anti-LAG-3 antibodies, adoptive cell therapy, and other novel agents in melanoma

Audience Question and Answer

Closing Thoughts

Faculty

Program Director
Jeffrey S. Weber, MD, PhD

Deputy Director
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
Professor of Medicine
NYU Grossman School of Medicine
New York, New York

Faculty
Allison S. Betof-Warner, MD, PhD

Assistant Member
Assistant Attending Physician
Melanoma Service
Division of Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty
Hussein Tawbi, MD

Associate Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Target Audience
This educational program is intended for oncologists and other healthcare professionals involved in the care of patients with melanoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess clinical trial evidence to incorporate existing and recently approved adjuvant therapies in appropriately identified patients after surgical removal of primary melanoma
  • Determine key factors critical to aid the selection of adjuvant, first-line and later lines of therapy for patients with metastatic BRAF wild-type or BRAF-mutated melanoma
  • Appraise clinical trial evidence optimize incorporation of targeted and immunotherapeutic approaches for metastatic BRAF-mutated melanoma including patients with brain metastases
  • Manage specific disease-related complications or adverse events associated with immune checkpoint inhibitors, targeted therapies, and other systemic treatments for melanoma and offer optimal management strategies to minimize adverse events
  • Evaluate ongoing clinical trials investigating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies in advanced melanoma

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.